This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1999 Nov;17(11):3692-3.

doi: 10.1200/JCO.1999.17.11.3692.

CD20-negative relapse after (131)I-anti-CD20 therapy

P Venugopal, W T Leslie, T O'Brien, S A Gregory

PMID: 10550173
DOI: 10.1200/JCO.1999.17.11.3692

Case Reports

CD20-negative relapse after (131)I-anti-CD20 therapy

P Venugopal et al. J Clin Oncol. 1999 Nov.

. 1999 Nov;17(11):3692-3.

doi: 10.1200/JCO.1999.17.11.3692.

Authors

P Venugopal, W T Leslie, T O'Brien, S A Gregory

PMID: 10550173
DOI: 10.1200/JCO.1999.17.11.3692

No abstract available

PubMed Disclaimer

Comment on

Peripheral T-cell lymphoma after anti-CD20 antibody therapy.
Tetreault S, Abler SL, Robbins B, Saven A. Tetreault S, et al. J Clin Oncol. 1998 Apr;16(4):1635-7. doi: 10.1200/JCO.1998.16.4.1635. J Clin Oncol. 1998. PMID: 9552080 No abstract available.
CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
Kinoshita T, Nagai H, Murate T, Saito H. Kinoshita T, et al. J Clin Oncol. 1998 Dec;16(12):3916. J Clin Oncol. 1998. PMID: 9850038 No abstract available.

Similar articles

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H. Maeshima AM, et al. Am J Surg Pathol. 2013 Apr;37(4):563-70. doi: 10.1097/PAS.0b013e3182759008. Am J Surg Pathol. 2013. PMID: 23426122
Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.
Micallef IN, Kirk A, Norton A, Foran JM, Rohatiner AZ, Lister TA. Micallef IN, et al. Blood. 1999 Apr 1;93(7):2427-8. Blood. 1999. PMID: 10215354 No abstract available.
[Monoclonal antibody therapy for non-Hodgkin's lymphoma].
Paul F, Rossi JF, Cartron G. Paul F, et al. Rev Prat. 2010 Jan 20;60(1):59-63. Rev Prat. 2010. PMID: 20222313 French.
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B, Santos ES. Collins-Burow B, et al. Expert Rev Anticancer Ther. 2007 Mar;7(3):257-73. doi: 10.1586/14737140.7.3.257. Expert Rev Anticancer Ther. 2007. PMID: 17338647 Review.
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R, Hagenbeek A. Marcus R, et al. Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x. Eur J Haematol Suppl. 2007. PMID: 17206982 Review.

See all similar articles

Cited by

OX40+ T lymphocytes and IFN-γ are associated with American tegumentary leishmaniasis pathogenesis.
Domingos PL, Viana AG, Fraga CA, Bonan PR. Domingos PL, et al. An Bras Dermatol. 2012 Nov-Dec;87(6):851-5. doi: 10.1590/s0365-05962012000600005. An Bras Dermatol. 2012. PMID: 23197203 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.